Veeva Vault CTMS launched at Bristol Myers Squibb to simplify clinical trial processes globally

Uniting Bristol Myers Squibb and Celgene on One Clinical Trial Management System, Company Launches Vault CTMS at Record Speed

Modernization streamlines trial management to speed drug delivery to patients

PLEASANTON, Calif., April 21, 2022 /PRNewswire/ — Veeva Systems announced today that Bristol Myers Squibb has implemented Veeva Vault CTMS globally to drive end-to-end trial management. The new CTMS replaced an older Celgene CTMS and an older Bristol Myers Squibb CTMS and is tightly integrated with Veeva’s eTMF and Study Startup applications. The total duration of implementation was less than 20 months.

By launching Veeva’s industry-leading trial management and monitoring solution enterprise-wide, Bristol Myers Squibb has established unified, agile, and simple trial processes to make clinical trials faster and easier. more efficient.

“We are excited to extend our long-standing partnership with Veeva in the area of ​​R&D,” said Greg Meyers, chief digital and technology officer at Bristol Myers Squibb. “Veeva’s continued commitment to customer success and product innovation helps us accelerate drug development and delivery to patients around the world. »

“Bristol Myers Squibb is one of our most agile and forward-thinking partners,” said Veeva CEO. Peter Gassner. “The merger of Bristol Myers Squibb and Celgene was the largest IT integration project in the history of the pharmaceutical industry and to have completed a single CTMS implementation in twenty months is truly remarkable. We are very proud to have crossed this step together.”

“Veeva Vault CTMS provides customers with advanced features that can simplify the execution of large-scale trials,” said Henry Gallion, Vice President, Veeva Vault CTMS. “Thank you to the team at Bristol Myers Squibb for your incredible partnership on this very important and complex CTMS implementation.”

About Veeva systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a public benefit company, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit

Veeva forward-looking statements
This release contains forward-looking statements regarding Veeva products and services and expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this press release and we undertake no obligation to update these statements. There are numerous risks that could adversely impact our results, including the risks and uncertainties disclosed in our Form 10-K filing for the period ended January 31, 2022that you can find here (you will find a summary of the risks that could impact our business on pages 13 and 14) and in our subsequent filings with the SEC, which you can access at

Deivis Mercado
Veeva Systems
[email protected]

SOURCE Veeva Systems